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Theodore Roosevelt [1] said: ‘‘Optimism is a good char-
acteristic but if carried to excess becomes foolishness.’’
Something similar—but less eloquent—might often have
been said by a paediatric intensivist to a haematology/
oncology colleague. Or worse: a senior colleague once
asked: ‘‘Why do we put nails in coffin lids?’’ Before the
punchline: ‘‘To stop the oncologists giving one more
round of chemo.’’ This is clearly now (and was then) an
absurd exaggeration. But perhaps what lies behind this
tension is captured in Roosevelt’s [1] next line: ‘‘We are
prone to speak of the resources of this country as inex-
haustible. This is not so.’’ Neither are paediatric intensive
care resources inexhaustible. Therefore, intensivists are
used to balancing costs and benefits of aggressive or
palliative treatment. We, consciously or unconsciously,
ration our limited resources [2]. But could bad outcomes,
such as those perceived for children with cancer, become
a self-fulfilling prophecy with out-of-date risks informing
plans to withdraw or withhold treatments? How do we
avoid circular arguments wherein our perceptions of poor
prognosis may contribute to poor outcomes in the plans
we make with families or the intensity of the support we
offer?
The answer is in large, systematically collected data
sets. Many paediatric intensivists are aware that the pae-
diatric index of mortality (PIM score) [3, 4]—now in its
third full iteration (PIM3) [5]—describes a much higher
PICU mortality for the same admission physiology
amongst haematology/oncology cases than the general
PICU population. The terms ‘leukaemia/lymphoma out-
side of first induction’ or ‘bone marrow transplant
recipient’ both represent ‘very high-risk’ diagnoses. In
53,112 recent cases, either of these fields carries a fivefold
greater risk of death with equivalent severity of organ
failure at admission. This is the same tariff as a cardiac
arrest preceding PICU admission [5].
This dismay-inducing comparison needs to be seen in
the light of the knowledge of the haematologist/oncologist
that many children with cancer (38 % at some point in
their illness) will be admitted at to a PICU [6]. And they
know that their meticulous cancer registry data show
impressive and improving results. Five-year survival for a
child with cancer is now at 83 % [7]. So for a haema-
tologist/oncologist, PICU is a frequent stopover on a
pathway to cure.
To try to understand and reconcile these differing
assessments of risk and benefit, we must be precise in our
descriptions of patients. Zinter et al. [8] have provided a
description of outcomes for 10,365 paediatric cancer
emergency admissions out of 246,346 admissions to the
US virtual PICU systems database. The overall mortality
was only 6.8 %. We should take note of this number. It is
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lower than most series quote for previously healthy
children with community-acquired sepsis or acute respi-
ratory distress syndrome (ARDS) on PICU [9–12]. The
observed relative risk of PICU death is still highly sig-
nificant at 2.9 (95 % CI 2.7–3.1), but the truth is that this
reflects the overall improvement in PICU outcomes more
than cancer lagging behind. Indeed, if we compare the
predicted risk of mortality for a child with sepsis-induced
multiple organ dysfunction syndrome (MODS) or ARDS,
with and without a high risk category of ‘leukaemia/
lymphoma outside of first induction’ through each of the
four published versions of the PIM scores since 1997, we
see that the outcomes for cancer cases have been mod-
elled as improving much faster than those of healthy
children (Fig. 1). These results challenge us to understand
the underlying mechanisms and to further refine and
reflect on our practise. Similar trends have been observed
in adult haematology and cancer [13]. It is unclear if the
general improvements in ICU (e.g. early recognition and
treatment of sepsis, or low tidal volume ventilation in
ARDS) have been disproportionately effective in hae-
matology/oncology cases. This is a credible explanation
considering their higher baseline risk. Or does this arise
from a specific therapy relevant to haematology/oncol-
ogy? Certainly tumour lysis syndrome therapies are now
highly effective. The change in mortality for adult cancer
patients with ARDS is striking: 89 % mortality
1990–1995 vs. 52 % 2007–2011 [14]. This raises the
possibility of a greater gain from more widespread use of
non-invasive ventilation in this population [15, 16]. This
hypothesis is currently under investigation in children
(‘‘SCARF’’ trial ISRCTN82853500) and adults (‘‘IV-
NICTUS’’ trial NCT01915719).
There are more tantalising clues to the underlying
mechanisms in Zinter et al.’s paper. Acute myeloid leu-
kaemia was independently associated with high risk—
consistent with recent work [17]. This might reflect the
more immunosuppressive regimens. Certainly infection
remains an independent risk factor. However, we know
that the outcomes for neutropenic fever are now excellent
(case fatality rate 0.7 %, 95 % CI 0.2–2.1) [18]. So per-
haps these results also reflect toxicities of chemotherapy
that matter more in the context of critical illness (e.g.
cardiac toxicity of anthracyclines).
But we do not need speculation or further work,
however, to recognise at least one important result in this
paper: extracorporeal membrane oxygenation (ECMO) in
haematology/oncology patients was associated with a
50 % survival (18/36 cases). This contrasts with the still
dismal results for ECMO post haemopoietic stem cell
transplantation [19]. Perhaps this is one directly relevant
and clear distinction between optimism and foolishness?
Most in-hospital deaths occur following withdrawal of
intensive care. This clinical decision-making process is
now better informed by an increased understanding of
epidemiology as presented by Zinter. Further enrichment
is now required, describing patient pathways, mode of
death, and underlying pathophysiology. To do this we
need increased dialogue and sharing of data between
haematology/oncology and PICU. This should not be
difficult; after all we are two of the most successful, best-
resourced and high profile paediatric specialties. Both
Fig. 1 Predicted probability of death in the paediatric intensive
care unit from successive iterations of the paediatric index of
mortality score (PIM) with acute respiratory distress syndrome
(ARDS) or multiple organ dysfunction syndrome (MODS).
Examples with equivalent admission physiology, with and without
the high-risk diagnosis of ‘leukaemia/lymphoma outside first
induction’ are shown. The absolute (ARR) and relative risk
reductions (RRR) for haematology/oncology cases are greater than
for the non-high-risk cases in this period (PIM vs. PIM3, ARDS—
high risk: ARR 12.2 %, RRR 44.2 %; non-high risk: ARR 0 %,
RRR 0 %. MODS—high risk: ARR 28 %, RRR 56.2 %; non-high
risk: ARR 5.1 %, RRR 37 %)
1590
have developed rapidly in the last 40 years and constitute
a large proportion of the in-patient facilities, staff and
resources in tertiary children’s hospitals. We share a
preoccupation with infection and the immune response.
Most importantly both specialities have seen dramatic and
continuous improvements in outcome. Survival is now the
expected outcome for a cancer diagnosis or an episode of
critical illness in a child. Each has refined techniques
(mechanical ventilation or bone marrow transplant con-
ditioning) that have resulted in dramatic reductions in
iatrogenic harm and improved survival. Each has huge
(perhaps the largest?) impacts on child mortality. We
frequently share patients. Work like that of Zinter and
colleagues is essential to optimise this collaboration.
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